
    
      This is a follow-up study that is based on the bridging study of a recombinant human
      papillomavirus 16/18 bivalent vaccine in preadolescent girls(Unique Protocol
      ID:HPV-PRO-006,Identifiers: NCT02562508) .The investigators will recruit people who have
      participated in bridging study before and collect their serum samples to test the
      seroprevalence and geometric mean concentrations of anti-HPV16 and anti-HPV18 antibody on 54
      months after dose 1
    
  